Emma Andrus, Associate Editor

Dermatology Times is looking back on the top stories in dermatology from the month of December.

Dermatology Times is recapping our top expert interviews from the month of December.

The "whole body" study at Northwestern will be lead by Amy Paller, MD, begins soon.

Itisha S. Jefferson, a patient advocate and medical student, discusses the significance of new ICD-10 codes for CCCA and FFA, improving diagnosis and care.

Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.

Nemolizumab is intended for use in combination with topical corticosteroids and/or calcineurin inhibitors in this indication.

The approval is based on positive data stemming from the ADORING clinical trial program.

A study using proteome-wide association techniques identified novel protein biomarkers for atopic dermatitis.

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Investigating podiatry students' diagnostic accuracy and reasoning for dermatological lesions across skin tones using a mixed-method research approach.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Dermatology Times is recapping our top expert interviews from the month of November.

Data from Galderma's OLYMPIA 1 trial was recently published in JAMA Dermatology.

This study demonstrates the use of AI-driven image analysis, leveraging the ScarletredVision app and machine learning, to diagnose and assess onychomycosis.

Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Andrea Rosik, MS, PA-C, provides insights into managing challenging cases of atopic dermatitis.

The study is set to begin enrollment later this year.

ENS-002 targets S. aureus in atopic dermatitis.

2-year data show 75.7% of TNFi-IR patients maintained ACR50, 80.6% achieved PASI100, and pain and fatigue improvements were sustained.

The ILDS has named 6 young dermatologists from around the world as recipients of the 2025 Young Dermatologists International Achievement Awards for their contributions to dermatology.

In a Dermatology Times Case-Based Peer Perspective event, Terry Faleye, MPAS, PA-C, reviewed 2 cases of patients with vitiligo to discuss innovative treatments and emotional challenges with disease management.

A study showed NB-UVB phototherapy effectively reduced prurigo nodularis symptoms, with 80% of patients achieving full response.

RAD will join MJH's multichannel model, enhancing its educational impact in atopic dermatitis, alopecia areata, vitiligo, and eczema.

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

Catch up on coverage from the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.